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2Abstract
Inhibition of glycogen synthase kinase 3$ (GSK3$) as a consequence of its phosphorylation
by protein kinase B/Akt (PKB/Akt) has been implicated in cardiac myocyte hypertrophy in
response to endothelin-1 or phenylephrine.  We examined the regulation of GSK3" (which
we show to constitute a significant proportion of the myocyte GSK3 pool) and GSK3$ in
cardiac myocytes.  Although endothelin increases phosphorylation of GSK3 and decreases its
activity, the response is less than that induced by insulin (which does not promote cardiac
myocyte hypertrophy).  GSK3 phosphorylation induced by endothelin requires signalling
through the extracellular signal-regulated kinase 1/2 (ERK1/2) cascade and not the PKB/Akt
pathway, whereas the reverse is true for insulin.  Cardiac myocyte hypertrophy involves
changes in morphology, and in gene and protein expression.  The potent GSK3 inhibitor 1-
azakenpaullone increases myocyte area as a consequence of increased cell length whereas
phenylephrine increases both length and width.  Azakenpaullone or insulin promotes AP1
transcription factor binding to an AP1 consensus oligonucleotide, but this was significantly
less than that induced by endothelin and derived principally from increased binding of JunB
protein, the expression of which was increased.  Azakenpaullone promotes significant
changes in gene expression (assessed by Affymetrix microarrays), but the overall response is
less than with endothelin and there is little overlap between the genes identified.  Thus,
although GSK3 may contribute to cardiac myocyte hypertrophy in some respects (and
presumably plays an important role in myocyte metabolism), it does not appear to contribute
as significantly to the response induced by endothelin as has been maintained.
Keywords: Glycogen synthase kinase 3; cardiac myocytes; endothelin-1; insulin;
hypertrophy.
31.  Introduction
Glycogen synthase kinase 3 (GSK3) was originally identified as a Ser-/Thr-protein
kinase which phosphorylates and inhibits glycogen synthase [1].  In the preprandial or fasted
state, GSK3 is catalytically-active and glycogenolysis predominates.  On feeding, the insulin-
stimulated phosphorylation and consequent inhibition of GSK3 assists in promoting glycogen
synthesis and accumulation [2].  In this case, inhibition of GSK3 is mediated by the
signalling pathway which involves phosphoinositide 3-kinase (PI3K), 3-phosphoinositide-
dependent kinase 1 (PDK1) and protein kinase B/Akt (PKB/Akt).  However, it is now
recognised that GSK3 plays a much wider role in biological processes [3-7].  For example, it
is central to the developmentally-important Wnt/Frizzled/$-catenin pathway and this function
appears to be largely separate from its role in the regulation of glycogen metabolism [8-10].
Mammalian cells express two isoforms of GSK3 which exhibit a high degree of
sequence similarity in their catalytic domains, GSK3" (molecular mass ~ 51 kDa) and
GSK3$ (molecular mass ~ 47 kDa).  GSK3 is phosphorylated on at least two residues.  There
are 'facilitative' autophosphorylations of GSK3"(Tyr-279) and GSK3$(Tyr-216) required for
GSK3 activity [11-13], and there are regulatory phosphorylations of GSK3"(Ser-21) and
GSK3$(Ser-9) which inhibit its kinase activity [3-7].  PKB/Akt phosphorylates GSK3"(Ser-
21) and GSK3$(Ser-9), and these residues lie in a typical PKB/Akt consensus substrate motif
[14].  However, GSK3"(Ser-21)/GSK3$(Ser-9) are phosphorylated by other kinases which
also recognise the "PKB/Akt consensus sequence".  These include particularly the p70/p85-
ribosomal protein S6 kinases (S6K1 and S6K2) and the p90-ribosomal protein S6 kinases
(RSK1-4) [4,5,7,15].  The active form of GSK3 phosphorylates its substrates in a 'relay'
fashion which requires an initial 'priming' phosphorylation at a Ser-/Thr-residue lying four
4residues C-terminal (+4) to the Ser-/Thr- phosphorylated by GSK3, and this ‘priming’
phosphorylation is catalysed by one of several protein kinases [7].  The Ser(P)/Thr(P)
initially phosphorylated by GSK3 can serve subsequently as a priming phosphorylation for
any Ser-/Thr-residue lying in the -4 position.  These relays can be extended.  For example,
four GSK3 sites and a priming site are present between residues 641-657 in Homo sapiens
muscle glycogen synthase.
GSK3 is important in Wnt-dependent cardiac development and growth [16]. 
However, it has also been implicated in adaptive growth of the postnatal heart [17-21].  The
mammalian cardiac myocyte withdraws from the cell cycle in the perinatal period but
expands in size during the maturational growth of the organism.  In addition to maturational
growth, cardiac myocytes can undergo adaptive, hypertrophic growth in vivo or ex vivo in
response to an increase in cardiac workload [22,23], or to stimulation of a variety of
transmembrane receptors (e.g. the endothelin ETA receptor or the "1-adrenergic receptor)
[24-27].  In vivo, myocardial hypertrophy (to which the expanded cardiac myocytes
contribute) is a major adaptive response which allows the heart to accommodate any
physiological or pathological increase in loading that it encounters.  However, in chronic
pathological overloading (e.g. in hypertension), this adaptive phase may ultimately degrade
into the maladaptive state of heart failure [23,28].  One proposal is that catalytically-active
GSK3 inhibits the development of hypertrophy in the unstimulated myocyte, and inhibition
of GSK3 (particularly GSK3$) through PI3K-dependent signalling leads to hypertrophy
[17-21]. Although GSK3 may participate in the cardiac myocyte hypertrophy induced
by Gq-coupled protein receptor (GqPCR) agonists such as endothelin-1 (ET-1) acting at the
ETA receptor and adrenergic receptor agonists [17,18], it is by no means the only signalling
protein implicated in the response.  Others proteins/pathways include the extracellular signal-
5regulated kinase 1 and 2 (ERK1/2) cascade, other mitogen-activated protein kinase cascades,
and Ca2+-dependent signalling pathways [29-34].  Furthermore, ERK1/2 phosphorylate and
activate RSKs [35], for which GSK3 is a known substrate [15].  Here, we demonstrate
differential signalling to GSK3 from ET-1 and insulin, and we characterise the morphological
and transcriptional changes induced in cardiac myocytes by inhibiting GSK3 with a small
molecule inhibitor, 1-azakenpaullone [36].
2. Materials and methods
2.1.  Materials
Polyclonal antibodies to GSK3" and phospho-GSK3"(Ser-21)/phospho-GSK3$(Ser-
9), and the monoclonal antibody to GSK3$ were from Cell Signaling Technology (catalogue
nos. 9338, 9331 and 9315, respectively).  The monoclonal antibody to phospho-GSK3$(Tyr-
216), which also cross-reacts with phospho-GSK3"(Ser-279), was from BD Transduction
Laboratories (Pharmingen) (catalogue no. 612312).  The monoclonal antibody to cardiac
troponin T was from Stratech Scientific (catalogue no MS-295-P1).   Secondary/tertiary
antibodies and fluorescent mounting medium were from Dako.  Antibodies to AP-1
components were from Santa Cruz Biotechnology Inc. as follows: c-Jun, sc-45X; JunB, sc-
46X; JunD, sc-74X; c-Fos, sc-52X; FosB, sc-48X; Fra1, sc-605X; and Fra2, sc-171X.   [(-
32P]ATP, streptavidin-Texas Red, rainbow molecular weight markers, and Hyperfilm MP
were from GE Healthcare.  ET-1 was from Bachem.  Human Actrapid insulin was from Nova
Nordisk Pharmaceutical Limited.  PMA, Hoescht 33258 and other biochemicals were from
6Sigma-Aldrich Chemical Co.  LY294002 and U0126 were from Alexis.  1-Azakenpaullone
was from Calbiochem.
2.2.  Primary culture of neonatal rat cardiac myocytes and preparation of whole cell extracts
Myocytes were dissociated from the ventricles of 1- to 3-day-old Sprague-Dawley rat
hearts by an adaptation of the method of Iwaki et al. [26] as previously described [37]. 
Unless stated otherwise, cells were plated at a density of 4 × 106 cells/60 mm Primaria culture
dish (BD Biosciences) for 18 h in 15% (v/v) foetal calf serum, then serum was withdrawn for
the 24 h before experimentation.  Myocytes were exposed to ET-1 (100 nM), PMA (1 :M) or
insulin (50 mU/ml, 300 nM) with or without pre-treatment (for 10 min) with inhibitors. 
Following exposure to agonists, myocytes were washed in ice-cold phosphate-buffered saline
(PBS).  For whole cell extracts, myocytes were scraped into in 150 :l/dish of Buffer A [20
mM $-glycerophosphate pH 7.5, 20 mM NaF, 2 mM EDTA, 0.2 mM Na3VO4, 10 mM
benzamidine, 5 mM dithiotheitol (DTT), 300 :M phenylmethylsulphonyl fluoride (PMSF),
200 :M leupeptin, 2 :M microcystin LR, 10 :M trans-epoxy-succinyl-L-leucylamido-(4-
guanidino)-butane (E64), containing 1 % (v/v) Triton X-100].  Samples were incubated on
ice for 10 min and then centrifuged (10,000 × g, 5 min, 4°C).  The supernatants were
retained.
2.3.  Preparation of nuclear extracts
Nuclear extracts were prepared as previously described [38].  Cardiac myocytes (4 ×
106 cells/60 mm culture dish) were washed in ice-cold PBS and scraped into 150 :l ice-cold
7Buffer B (10 mM HEPES pH 7.9, 10 mM KCl, 1.5 mM MgCl2, 0.3 mM Na3VO4, 5 mM
DTT, 300 :M PMSF, 200 :M leupeptin, 2 :M microcystin LR, 10 :M E64).  Samples were
centrifuged (10,000 × g, 5 min, 4°C) and the pellets washed in 100 :l Buffer B containing
0.1% (v/v) Nonidet P40.  Samples were centrifuged (10,000 × g, 5 min, 4/C) and the pellets
resuspended in 50 :l Buffer C [20 mM HEPES pH 7.9, 420 mM NaCl, 1.5 mM MgCl2, 0.3
mM Na3VO4, 0.2 mM EDTA, 25% (v/v) glycerol, 5 mM DTT, 300 :M PMSF, 200 :M
leupeptin, 2 :M microcystin LR, 10 :M E64].  Suspensions were incubated on ice (1 h),
then centrifuged (10,000 × g, 5 min, 4/C) and supernatants transferred to Eppendorf tubes. 
Protein concentrations were determined by the Bradford method [39].  Extracts were snap-
frozen in liquid N2 and stored at -80/C.
2.4.  Immunoblot analysis
Samples were boiled with 0.33 vol of SDS-polyacrylamide gel electrophoresis sample
buffer [10% SDS (w/v), 13% glycerol (v/v), 300 mM Tris-HCl, pH 6.8, 130 mM DTT, 0.2%
bromophenol blue (w/v)].  Proteins [20 :g for total or nuclear extracts, 25 :l for Fast Protein
Liquid Chromatography (FPLC) fractions] were separated by SDS-polyacrylamide gel
electrophoresis using 10% (w/v) resolving gels and 6% (w/v) stacking gels, and transferred to
nitrocellulose as described previously [40].  Non-specific binding sites were blocked with 5%
(w/v) non-fat milk powder in TBST [20 mM Tris-HCl pH 7.5, 137 mM NaCl, 0.1% (v/v)
Tween 20].  Membranes were incubated (overnight, 4°C) with primary antibodies diluted in
TBST containing 1 % (w/v) bovine serum albumin.  Primary antibodies were used at the
following dilutions: GSK3", GSK3$ and phospho-GSK3"(Ser-21)/phospho-GSK3$(Ser-9),
1/1000; phospho-GSK3$(Tyr-216), 1/2000 for total extracts and 1/1000 for fractions from
8FPLC; JunB, 1/2000.  Antibodies to GSK3" and GSK3$ were mixed when simultaneous
detection was required.  Membranes were washed in TBST, incubated (60 min, room
temperature) with horseradish peroxidase- (HRP-) conjugated secondary antibodies (1/5000)
in TBST containing 1% (w/v) nonfat milk powder, and were then washed in TBST.  For
FPLC fractions immunoblotted for GSK3", GSK3$ or phospho-GSK3"(Ser-21)/phospho-
GSK3$(Ser-9), an amplification step with goat anti-rabbit/mouse immunoglobulin secondary
antibodies [1/5000 in TBST containing 1% (w/v) non-fat milk powder] was included,
followed by incubation with HRP-conjugated anti-goat immunoglobulin tertiary antibodies as
described above.  Bands were detected by enhanced chemiluminescence (Santa Cruz
Biotechnology Inc.) using Hyperfilm MP.
2.5.  Fast protein liquid chromatography (FPLC)
Myocytes (16 × 106) were scraped into Buffer D [25 mM HEPES pH 7.1, 2 mM
EDTA, 2 mM EGTP, 0.1 % (v/v) 2-mercaptoethanol, 5% (v/v) glycerol, 0.06% Brij 35, 0.3
mM Na3VO4 1 mM benzamidine] containing 1% Triton X100, 0.1 M NaCl, 300 :M PMSF,
200 :M leupeptin, 2 :M microcystin LR, and 10 :M E64.  Samples were centrifuged
(10,000 × g, 10 min, 4/C) and the supernatants were re-centrifuged.  Clarified supernatants
were applied to a MonoS HR5/5 column equilibrated with Buffer D containing 0.1 M NaCl
(preliminary screening experiments revealed that no GSK3 activity eluted below 0.1 M
NaCl).  The column was washed with Buffer D containing 0.1 M NaCl (5 ml) and proteins
were eluted using a linear NaCl gradient (0.1 - 0.3 M NaCl, 10 ml) at a flow rate of 1 ml/min
with collection of 0.5 ml fractions.  Samples from each fraction were assayed for GSK3
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2.6.  Assay of GSK3 activity
GSK3 activity in FPLC fractions was assayed by the incorporation of [(-32P]ATP into
a ‘primed’ phosphopeptide substrate (YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE [41],
synthesised by the Advanced Biotechnology Centre, Imperial College London) in the absence
or presence of 1-azakenpaullone (10 :M) to inhibit GSK3.  Column fractions (40 :l) were
added to 5 :l of Buffer E [50 mM Tris-HCl pH 7.5, 0.1 % (v/v) 2-mercaptoethanol, 100 :M
‘primed’ phosphopeptide substrate [41], with 100 :M 1-azakenpaullone when required]. 
Reactions were initiated by addition of 5 :l 1 mM ATP/100 mM MgCl2 containing 2 :Ci
[(-32P]ATP and incubations were for 20 min at 30°C.  Assays were terminated by spotting 40
:l of the reaction mixture onto Whatman P81 papers which were then washed in 75 mM
H3PO4 (4 × 15 min).  Radioactivity incorporated was determined by „erenkov counting. 
GSK3 activity was taken as the difference in 32P incorporation between assay in the absence
and presence of 1-azakenpaullone.
2.7.  Immunostaining and planimetry
Glass coverslips were placed in Primaria 35 mm culture dishes and coated with
gelatin [1% (v/v)] then laminin (20 :g/ml in PBS, 2 h, room temperature).  Dishes plus
coverslips were washed three times with PBS.  Myocytes were plated at 1.5 ×106 cells/dish in
serum (18 h).  Serum was withdrawn (24 h) and myocytes were exposed to 100 :M
phenylephrine, 10 :M 1-azakenpaullone, or 10 mM LiCl (24 h).  Cells were washed three
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times with PBS and fixed in 4% (v/v) formaldehyde (10 min, room temperature).  Following
permeabilisation with 0.3% (v/v) Triton X-100 (10 min, room temperature), non-specific
binding was blocked with 2.5 % (w/v) bovine serum albumin in 0.3% (v/v) Triton X-100 (10
min, room temperature).  Antibodies and fluorophores were diluted in PBS, all incubations
were at room temperature in a humidified chamber, and coverslips were washed three times
in PBS after each stage of the immunostaining procedure.  Myocytes were stained with
mouse monoclonal primary antibodies to phospho-GSK3"(Tyr-279)/phospho-GSK3$(Tyr-
216) (1/100, 60 min), with biotinylated anti-mouse immunoglobulin secondary antibodies
(1:200, 60 min) and streptavidin-Texas Red (1:200, 30 min).  Nuclei were stained with
Hoechst 33258 (50 :g/ml, 15 min).  Myocytes were stained or additionally counterstained
with mouse monoclonal primary antibodies to troponin T (1/40, 60 min) with
FITC-conjugated anti-mouse immunoglobulin secondary antibodies (1/200, 60 min). 
Coverslips were mounted using fluorescent mounting medium and viewed by fluorescence
microscopy.  Cardiac myocyte area was measured by digital planimetry (Scion Image Alpha
4.03, Scion Corporation, USA).  At least 100 myocytes were measured for a single
experiment and 4 independent experiments were conducted.  Maximum cell length and width
were also measured.  Results were normalised to the mean value for the control cells for each
experiment and results are presented as the means ± S.E.M. for the 4 independent
observations.
2.8.  Electrophoretic mobility shift assays (EMSAs)
An oligonucleotide probe containing the consensus AP1 sequence (5'-
CGCTTGATGACTCAGCCGGAA-3', AP1 sequence underlined, Santa Cruz Biotechnology
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Inc.) was 5'-radiolabelled (30 min, 37/C) in 12 :l containing 30 ng double-stranded
oligonucleotide, 10 units T4 polynucleotide kinase (Promega), 15 :Ci [(-32P]ATP and 1.2 :l
of commercial 10 × T4 kinase buffer (Promega).  Unincorporated [(-32P]ATP was removed
by centrifugation (700 × g, 3 min, room temperature) through pore size 10 Chromaspin
columns (BD Biosciences - Clontech) in 10 mM Tris-HCl pH 8.0, 1 mM EDTA.  The probe
was diluted to a working concentration of 0.4 ng/:l.
Cardiac myocyte nuclear extracts (10 :g protein) were incubated (10 min, room
temperature) with 4 :l Buffer F [50 mM Tris-HCl pH 7.5, 250 mM NaCl, 5 mM EDTA, 1
mM DTT, 25% (v/v) glycerol] and 1 :g poly dI-dC in a total volume of 20 :l.  Radiolabelled
probe (0.4 ng) was added and the mixture incubated (20 min, room temperature).  DNA-
protein complexes were separated by electrophoresis (120 V, 3 h) non-denaturing
polyacrylamide gels [5% (w/v) acrylamide, 0.166% (w/v) bisacrylamide, 0.05% (w/v)
ammonium persulphate, 0.1% (v/v) TEMED in Buffer G (45 mM Tris base, 45 mM H3BO4, 1
mM EDTA)] with Buffer G as running buffer.  Gels were dried (80/C, 45 min) onto
Whatman 3MM paper and exposed to Hyperfilm MP for 24 - 48 h at -80/C.  For supershift
assays, nuclear extracts (3 :g protein) were pre-incubated (1 h , 4/C) with 1-2 :g of primary
antibody and EMSAs then performed as described.
2.9.  RNA preparation and microarray analysis.
Myocytes (4 × 106 cells/condition) were unstimulated, or were exposed to 10 :M
1–azakenpaullone or 100 nM ET-1 for 60 min.  Total RNA was extracted, and cRNA
synthesised from 10 :g total RNA and purified as described [42].  To minimise the effects of
variation between separate myocyte preparations, equal amounts of RNA were pooled from 3
independent experiments prior to cRNA synthesis.  Three separate experiments were
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performed for each condition (i.e. 9 myocyte preparations in total).  Fragmentation of
antisense cRNA and hybridisation to Affymetrix rat genome 230 2.0 arrays were performed
at the CSC Microarray Centre (Hammersmith Campus, Imperial College London) according
to their standard protocols (microarray.csc.mrc.ac.uk).  The MIAME-compliant data were
exported to ArrayExpress (E-MIMR-681).  Preliminary analysis of hybridisation data was
with Affymetrix GeneChip Operating System, GCOS.  The data were imported into
GeneSpring GX 7.3.1 (Agilent Technologies) as tab-delimited text files.  Log10 values were
used for analysis with values set to a minimum of 0.01 and, for each data-set, the data were
normalised per array (to the 50th percentile) and values for each probe set were normalised to
the corresponding controls (prepared and hybridised simultaneously).  A confidence filter
was applied and genes were selected if present or marginal in all controls, all samples from
myocytes exposed to 1-azakenpaullone or all samples from myocytes exposed to ET-1. 
One-way non-parametric t-tests were performed for each transcript for each condition
relative to the appropriate controls (GeneSpring GX).  The false discovery rate was set to
<0.05 and multiple testing correction performed using the Benjamini and Hochberg false
discovery rate algorithm.  Transcripts were filtered on the basis of >2-fold difference.  All
genes were confirmed by BLAST search and were correct as of August 2007.
2.10.  Quantitative PCR (qPCR)
RNA was extracted and cDNA synthesized using reverse transcription as previously
described [42].  qPCR was performed using a Real-Time PCR System model 7500 (Applied
Biosystems).  Amplifications were carried out in optical 96-well reaction-plates (Applied
Biosystems) with each well containing 12.5 :l of SYBR Green Jump Start Taq Readymix
(Sigma Aldrich Chemical Co.), 5 :l of oligonucleotide primers (5 pmol each of forward and
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reverse primers) and 7.5 :l of cDNA template (diluted 15-fold in water).  Primers used were
as follows: prostaglandin-endoperoxide synthase 2 (Ptgs2, also known as cyclooxygenase 2,
accession no. NM_017232), forward primer: 5'-CAAGACAGATCAGAAGCGAG-3'
(712-731), reverse primer: 3'-GTCTGTCTAGAGTTTCACCG-5' (784-803), 92 bp product;
cyclin G2 (Ccng2_predicted, accession no. XM_223270), forward primer: 5'-
ACTGCACTATGAGCTGGAAG-3' (558-577), reverse primer: 3'-
ATCGAGGCTCAGAACTTCCT-5' (644-663), 106 bp product; adrenomedullin (accession
no. NM_012715), forward primer: 5'-GCTCGTTGATGAGAAGACAG-3' (336-355), reverse
primer: 3'-GGTAGCGTTTGACTCGAATG-5' (435-454), 119 bp product; glyceraldehyde 3-
phosphate dehydrogenase (Gapd, accession no. NM_017008), forward primer: 5'-
GCTGGCATTGCTCTCAATGACA-3' (1738-1759), reverse primer: 3'-
TCCACCACCCTGTTGCTGTA-5' (1801-1820), 83 bp product.  qPCR analysis of Gapd was
performed as a control and the relative quantification protocol was used.  PCR conditions for
all primer pairs were 50/C for 2 min, 95/C for 10 min (Jump-Start Taq polymerase activation
step), followed by 40 cycles of 95/C for 15 s and 59/C for 60 s.  Following qPCR,
dissociation curve analysis was routinely performed to check for aberrant amplification
products (e.g. primer-dimers).
2.11.  Densitometry and statistical analysis
For immunoblots and EMSA autoradiographs, bands were quantified by scanning
densitometry using Imagemaster 1D calibrated with Kodak photographic step tablet no. 2
(GE Healthcare).  Statistical analysis was performed using GraphPad Prism.  One-way
ANOVA (repeated measures where appropriate) was used with a multiple comparison test
(Tukey for full multiple testing; Dunnett for testing against controls only).
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3.  Results
3.1.  Stimulation of phosphorylation of GSK3"(Ser-21) and GSK3$(Ser-9) in cardiac
myocytes by ET-1, PMA or insulin
Immunoblot analysis demonstrated that both GSK3" and GSK3$ are expressed in
cardiac myocytes (Fig. 1A-C, lower panels).  Using phosphorylation site-specific antibodies,
we showed that maximally-effective concentrations (data not shown) of ET-1 (100 nM),
PMA (1 :M) or insulin (300 nM) promoted rapid increases (maximal in 2-5 min) in the
phosphorylation of GSK3"(Ser-21) and GSK3$(Ser-9) (Fig. 1A-C, upper panels;
quantification in Fig. 1D and E).  Phosphorylation remained relatively constant over the 5 -
30 min period.  The relative increases in phosphorylation of GSK3"(Ser-21) and
GSK3$(Ser-9) compared with zero-time controls were apparently greater for insulin than for
ET-1 or PMA.  A direct comparison of the effects of the three agonists (20 min) confirmed
this to be the case (Fig. 1F, quantification in Fig. 1G).
GSK3"(Ser-21)/GSK3$(Ser-9) may be phosphorylated by a variety of protein
kinases lying downstream from either PI3K (i.e. PKB/Akt) or the ERK1/2 cascade (e.g.
RSKs) [4,5,7].  U0126 and LY294002 are widely used as inhibitors of the ERK1/2 cascade
[43] and of PI3K [44], respectively.  U0126 reduced the phosphorylation of GSK3"(Ser-21)
and GSK3$(Ser-9) stimulated by ET-1 (Fig. 2A, D and E) or PMA (Fig. 2B, D and E),
whereas LY294002 was largely ineffective.  Conversely, LY294002 reduced the
phosphorylation of GSK3"(Ser-21) and GSK3$(Ser-9) stimulated by insulin (Fig. 2C, D and
E), whereas U0126 was largely ineffective.  Thus, ET-1 and PMA induce phosphorylation of
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GSK3"(Ser-21) and GSK3$(Ser-9) primarily through the ERK1/2 cascade, whereas insulin
induces phosphorylation primarily through PI3K.
3.2.  Phosphorylation of GSK3"(Tyr-279) and GSK3$(Tyr-216)
Phosphorylation of GSK3"(Tyr-279) and GSK3$(Tyr-216) is essential for their
catalytic activity.  Although there have been reports that agonists cause dephosphorylation or
phosphorylation of these residues and this represents a means whereby GSK3 can be
inhibited or activated in intact cells [45-48], this is not necessarily the case [7,13,49].  We
examined the phosphorylation of GSK3"(Tyr-279) and GSK3$(Tyr-216) in cardiac
myocytes.  The monoclonal antibody to phospho-GSK3$(Tyr-216) cross-reacts with
phospho-GSK3"(Ser-279), presumably because the amino acid sequences of residues 190-
305 in rat GSK3$ (accession no. NP_114469) and residues 253-368 in rat GSK3" (accession
no. NP_059040) are identical.  We detected phospho-GSK3"(Tyr-279) and phospho-
GSK3$(Tyr-216) in approximately equal apparent abundances (Fig. 3A-C).  Assuming that
the affinity of the monoclonal antibody for both GSK3 isoforms is similar (because of the
sequence identity) and that GSK3"(Tyr-279) and GSK3$(Tyr-216) are stoicheiometrically
phosphorylated [13], this suggests that GSK3" contributes significantly to the GSK3
complement in cardiac myocytes and cannot be ignored.  However, there were not any
changes in the phosphorylation of GSK3"(Tyr-279) or GSK3$(Tyr-216) in cardiac myocytes
treated with ET-1 (Fig. 3A), PMA (Fig. 3B) or insulin (Fig. 3C) over 30 min.
The phosphorylation of GSK3"(Tyr-279) and GSK3$(Tyr-216) probably represents
autophosphorylation.  Chemical inhibition of GSK3 leads to dephosphorylation of
GSK3"(Tyr-279) and GSK3$(Tyr-216) in other cells [7,13].  In cardiac myocytes exposed to
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the GSK3 inhibitor, 1-azakenpaullone (10 :M) [36], the total pool of GSK3$ did not change,
but phospho-GSK3"(Tyr-279) and phospho-GSK3$(Tyr-216) declined over a 12 h period
(Fig. 3D and E).  Phospho-GSK3"(Tyr-279) was apparently more rapidly dephosphorylated
than phospho-GSK3$(Tyr-216).  These data are consistent with the view that
phosphorylation of GSK3"(Tyr-279) and GSK3$(Tyr-216) represents an
autophosphorylation [7,13].  However, we do not know the mechanism of the
dephosphorylation, nor do we understand its differential nature for the two GSK3 isoforms. 
Dephosphorylation (Fig. 3D and E) could represent a genuine dephosphorylation as a result
of protein Tyr-phosphatase activity.  Alternatively, turnover of phospho-GSK3"(Tyr-279)
and phospho-GSK3$(Tyr-216) proteins through protein degradation and resynthesis of
GSK3 in the absence of autophosphorylation would lead to apparent dephosphorylation.  In
this regard, Cole et al. [13] have presented data with protein synthesis inhibitors suggesting
that the dephosphorylation reflects a genuine phosphatase activity rather than protein
turnover.
3.3.  Fast Protein Liquid Chromatography separation of GSK3 
GSK3"/GSK$ were partially purified by MonoS FPLC of cardiac myocyte extracts
from unstimulated cells and from cells exposed to ET-1 or insulin.  Column fractions were
assayed GSK3 activity and immunoblotted for phospho-GSK3"(Tyr-279)/phospho-
GSK3$(Tyr-216), phospho-GSK3"(Ser-21)/phospho-GSK3$(Ser-9) and total GSK3$ (Fig.
4).  GSK3 activity eluted as a broad peak between 0.11 - 0.22 M NaCl (fractions 11-20) with
a small shoulder (particularly apparent using control extracts) in fractions 13-14 (Fig. 4A). 
Total GSK3 activities (obtained by integrating areas under the peaks) were reduced by 54.2 ±
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1.4% with insulin and 31.9 ± 6.4% with ET-1 (Fig. 4B).  Thus, both insulin and ET-1 inhibit
GSK3, but perhaps not to the extent that might have been anticipated.
Antibodies to phospho-GSK3"(Tyr-279)/phospho-GSK3$(Tyr-216) proved effective
for the detection of total GSK3 (i.e. both isoforms) by immunoblotting (Fig. 4C) and were
used routinely for this purpose.  Although total GSK3$ antibodies were satisfactory for
detecting protein in FPLC fractions, total GSK3" antibodies did not detect any bands.
Phospho-GSK3"(Tyr-279) eluted predominantly in fractions 12-17, with phospho-
GSK3$(Tyr-216) eluting in fractions 14-20 (Fig. 4C).  GSK3$ immunoreactivity reflected
phospho-GSK3$(Tyr-216) immunoreactivity (Fig. 4D).  Thus, GSK3$ probably constitutes
the majority of GSK3 activity in fractions 15-19 (Fig. 4A), and may indeed constitute the
majority of GSK3 activity overall.  GSK3" probably accounts for the shoulder of GSK3
activity in fractions 13-14 (Fig. 4A).  A significant proportion of phospho-GSK3"(Tyr-
279)/phospho-GSK3$(Tyr-216) (or total GSK3$) eluted in fractions 2-4 of the isocratic
wash (Fig. 4C), but there was no detectable GSK3 activity (data not shown).  This pool of
GSK3 did not bind to MonoS columns even in the total absence of any NaCl in the extraction
buffer (myocytes were routinely extracted in 0.1 M NaCl).  There were no gross changes in
the elution profiles of phospho-GSK3"(Tyr-279) or phospho-GSK3$(Tyr-216) (or, indeed,
total GSK3$) in cells treated with ET-1 or insulin.
The phospho-GSK3"(Ser-21)/phospho-GSK3$(Ser-9) antibodies detected little
immunoreactivity in FPLC fractions from control extracts, but immunoreactivity was readily
detected in fractions 13-18 using extracts of myocytes exposed to ET-1 or insulin (Fig. 4E). 
We directly compared fractions obtained from control myocytes and myocytes exposed to
ET-1 or insulin (Fig. 4F).  ET-1 or insulin increased phospho-GSK3"(Ser-21)/phospho-
GSK3$(Ser-9) (relative to controls) in the fractions from the isocratic wash and in gradient
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fractions 16-18, with insulin having the greater effect.  The increase in phospho-GSK3"(Ser-
21)/phospho-GSK3$(Ser-9) immunoreactivity in fractions 2-3 (Fig. 4E and F) implies that
phosphorylation of GSK3"(Ser-21) and GSK3$(Ser-9) in this pool can be increased over
control values.  Thus, the absence of GSK3 activity in fractions 2-3 does not result from the
fact that GSK3"(Ser-21) and GSK3$(Ser-9) in these fractions are already fully
phosphorylated.
3.4.  Subcellular localisation of GSK3 and the morphological effects of its inhibition in
cardiac myocytes
Subcellular localisation of GSK3 was assessed by immunostaining with antibodies to
phospho-GSK3"(Tyr-279)/phospho-GSK3$(Tyr-216) with counterstaining of nuclei by
Hoechst 33258 (Fig. 5A and B).  Myocyte identity was confirmed by troponin T
immunostaining (data not shown).  Phospho-GSK3"(Tyr-279)/phospho-GSK3$(Tyr-216)
immunostaining was strongest in myocyte nuclei, with considerably less in the cytoplasm
(Fig. 5A).  There were no gross changes in phospho-GSK3"(Tyr-279)/phospho-GSK3$(Tyr-
216) localisation in cells exposed to ET-1 or insulin for 20 min (data not shown).
We compared the effects of inhibitors of GSK3 (1-azakenpaullone or LiCl) and the "-
adrenergic agonist, phenylephrine (a powerful hypertrophic agonist) on cardiac myocyte
morphology.  Phenylephrine promoted increased cardiac myocyte area (Fig. 5C and D).  This
was associated with increases in maximum cell length and width (Fig. 5E and F) such that the
maximum length:maximum width ratio was increased to only a small extent compared with
controls (Fig. 5G).  Cardiac myocyte area was also increased by 1-azakenpaullone (Fig. 5C),
but this primarily reflected increased cell length in the absence of any increase in cell width
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(Fig. 5E and F).  Consequently, the maximum length:maximum width ratio was significantly
increased (Fig. 5G).  There was a small increase (42 ± 5 %) in the area of cells exposed to
LiCl (Fig. 5D), but this did not reach statistical significance.
3.5.  Transcription factor binding to the AP1 consensus sequence
The AP1 transcription factor complex is a homodimer of Jun family members (c-Jun,
JunB and JunD) or a heterodimer of Jun family members and Fos family members (c-Fos,
FosB, Fra1 and Fra2), though not all combinations are allowed [50,51].  GSK3
phosphorylates the C-terminal regions of Jun family transcription factors at sites proximal to
their DNA binding domains, and this decreases their affinity for AP1 consensus sequences
and their transactivating potential [52].  Conversely, inhibition of GSK3 and
dephosphorylation of the GSK3 sites in the Jun family increases their transactivating
potential.  We examined the abilities of 1-azakenpaullone, insulin and ET-1 to increase
binding of nuclear proteins to an AP1 oligonucleotide using EMSAs (Fig. 6A and B).  ET-1
was the most effective agonist, but both 1-azakenpaullone and insulin were moderately
effective (Fig. 6A and B).  Antibodies to JunB clearly supershifted the bands after exposure
of cells to each of the three agonists (Fig. 6C).  Antibodies to other potential AP1
components produced a subshift (c-Fos) or reduced binding (for FosB, JunD or Fra2)
suggesting that they may be involved, but there was no consistency between the three
agonists.
Increased binding of JunB to AP1 sequences could reflect an increase in abundance or
an increase in affinity caused by a reduction in phosphorylation of Ser-/Thr- residues
proximal to the C-terminal DNA region.  1-Azakenpaullone (Fig. 6D) or insulin (Fig. 6E)
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increased the abundances of JunB within 1 h, which may well explain the increase in binding
to AP1 (Fig. 6A-C).  By analogy with human JunB [52], rat JunB should contain GSK3
phosphorylation sites at Ser-248 and Thr-252, the priming phosphorylation being on Ser-256. 
We do not know whether there is a decrease in phosphorylation of these residues as well as
an increase in abundance following inhibition of GSK3.  The only available phosphopeptide
antibody detects the priming phosphorylation (Ser-259 in Homo sapiens JunB).  Not
unexpectedly, we were unable to detect any changes in the phosphorylation state of this
residue with 1-azakenpaullone, insulin or ET-1 (data not shown).
3.6.  Changes in gene expression
Since GSK3 appears to be localised predominantly to the nucleus in cardiac myocytes
and 1-azakenpaullone increases AP1 transcription factor binding to a consensus sequence, we
examined the effects of 1-azakenpaullone (1 h) on global gene expression in cardiac
myocytes using Affymetrix rat genome 230 2.0 arrays.  In response to 1-azakenpaullone, we
identified significant changes in expression (FDR<0.05; 2-fold minimum change) in 26
established, protein-coding genes (Table 1).  This contrasts with 127 established genes with
significant changes in expression induced by ET-1 at 1 h (A. Clerk et al., manuscript
submitted).  Although expression of 12 genes was altered by 1-azakenpaullone or ET-1, only
two were changed to a similar extent in response to either agonist.  For 5 genes, the response
to ET-1 was substantially greater than that induced by 1-azakenpaullone and a further 5
demonstrated opposing changes (i.e. 1-azakenpaullone promoted a decrease in expression
whereas ET-1 increased expression).  Overall, the effect of 1-azakenpaullone on gene
expression did not resemble that induced by ET-1 suggesting that any effect of ET-1 on
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GSK3 activity does not necessarily influence changes in gene expression associated with
hypertrophy.  It is worth noting that 1-azakenpaullone did not increase the abundance of
JunB mRNA above our nominal threshold value (2-fold).  The increase in JunB protein
induced by 1-azakenpaullone (Fig. 6D) may therefore reflect decreased degradation of JunB
protein.
To validate the changes in gene expression induced by 1-azakenpaullone, we used
qPCR to examine a more detailed time course for expression of prostaglandin-endoperoxide
synthase 2 (Ptgs2, also known as cyclooxygenase 2), cyclin G2 (Ccng2) and adrenomedullin. 
Consistent with the microarray data (Table 1), expression of Ptgs2 mRNA was increased at
60 min (Fig. 7A).  This increase was transient and expression declined almost to basal levels
by 2 h.  Ccng2 (Fig. 7B) and adrenomedullin (Fig. 7C) mRNAs were both decreased in
expression with maximal decreases occurring at 60 - 90 min.
4. Discussion
In addition to participating in the Wnt/Frizzled pathway during cardiac development
[16], inhibition of GSK3 has recently been implicated in the development of cardiac
hypertrophy [20,21].  In cultured cardiac myocytes, $-adrenergic stimulation induces aspects
of the hypertrophic response in a manner dependent on the activation of PI3K and PKB/Akt,
and the subsequent inhibition of GSK3$ [17].  Similar conclusions have been drawn with
ET-1 or phenylephrine as agonists, or by using chemical inhibition of GSK3 with LiCl [18]. 
These ex vivo observations were extended with the in vivo finding that raising left
intraventricular pressure by transverse aortic constriction (TAC, a pro-hypertrophic
intervention) inhibits GSK3 activity [18].  Furthermore, a transgenic mouse in which a
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constitutively-active (non-phosphorylatable) form of GSK3$ [GSK3$(Ser-9Ala)] is
cardiospecifically expressed showed reduced hypertrophy in response to overexpression of
constitutively-active calcineurin, infusion of isoprenaline or TAC [19].  There were no
obvious effects of GSK3$(Ser-9Ala) in unmanipulated control mice (although others have
reported that cardiospecific overexpression of wild type GSK3$ impairs post-natal growth of
cardiac myocytes [53]).  Thus, stimulation of the catalytic activity of GSK3 could represent
an anti-hypertrophic intervention, possibly with therapeutic potential.  Potentially contrasting
with the proposed anti-hypertrophic action, a pro-apoptotic role of GSK3 activation has been
identified in adult cardiac myocytes [48] and other cells [54].  Furthermore, cardiospecific
overexpression of wild-type GSK3$ causes contractile dysfunction, possibly as a result of
disturbances in Ca2+ movements [53].  These experiments [48,53] suggest that activation of
GSK3 might be deleterious.  However, it is worth noting that, in vivo, replacement of the
wild-type GSK3" and GSK3$ genes with transgenes encoding constitutively-active GSK3"
and GSK3$ [GSK3"(Ser21Ala)/GSK3$(Ser9Ala) 'knock-in' mice] does not appear to
interfere with survival or baseline cardiac function [55,56].  In this situation, the fully-active
mutant proteins in the ‘knock-in’ situation are expressed in the same abundances as the wild-
type proteins in the wild-type animals, thus simulating the in vivo situation, rather than being
overexpressed.
Here, we have extended the characterisation of GSK3 in the heart.  Past reports have
emphasised a predominant role for GSK3$ (as opposed to GSK3") in cardiac myocyte
hypertrophy.  However, both isoforms are clearly expressed (Fig. 1A-C).  Assuming that the
phospho-GSK3$(Tyr-216) antibody has similar affinity for phospho-GSK3"(Tyr-279) as for
phospho-GSK3$(Tyr-216) (see section 3.2), results shown in Fig. 3A-C suggest that GSK3"
and GSK3$ are present in approximately equal mass abundances in cardiac myocytes.  In
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terms of activity under basal conditions, a combination of MonoS FPLC and immunoblotting
with anti-phospho-GSK3$(Tyr-216) suggests that GSK3$ activity predominates over
GSK3" activity by a factor of 5- to 10-fold (Fig. 4A and C).  However, the catalytic activity
of GSK3" is probably important in the heart.  Unlike the situation in skeletal muscle where
GSK3$ activity seems the more important [55], GSK3" does participate significantly in the
regulation of cardiac glycogen metabolism [56].  It is not known whether there is any GSK3
isoform specificity in terms of additional functional consequences in the heart.  In whole
animals and isolated cells, both similarities and differences between GSK3" and GSK3$
have been detected [55-58].  We therefore believe that a role for both GSK3" and GSK3$
particularly in myocyte hypertrophy should be considered.
Published studies emphasise the importance of PKB/Akt in the phosphorylation and
inhibition of GSK3 by hypertrophic GPCR agonists [17,18,59].  However, GSK3 may be
phosphorylated by other protein kinases.  In cardiac myocytes, ET-1 and PMA rapidly and
powerfully activate ERK1/2 [60] whereas they only weakly activate PKB/Akt [61,62]. 
Conversely, insulin is a powerful activator of PKB/Akt, but is ineffective in activating
ERK1/2 [62,63].  Thus, the separate roles of these two signalling pathways can be partially
delineated in cardiac myocytes by the use of these ‘selective’ agonists.  Insulin at maximally-
effective concentrations causes the largest increase in phosphorylation of GSK3"(Ser-
21)/GSK3$(Ser-9), with ET-1 or PMA being approximately half as effective (Fig. 1F and G)
implying that PKB/Akt mediates insulin-stimulated phosphorylation of GSK3 and ERK1/2
mediate phosphorylation in response to ET-1 or PMA.  Consistent with this, U0126 inhibits
the phosphorylation of GSK3"(Ser-21) and GSK3$(Ser-9) induced by ET-1 or PMA, but not
insulin (Fig. 2).  Conversely, LY294002 inhibits phosphorylation of GSK3"(Ser-21) and
GSK3$(Ser-9) induced by insulin, but not ET-1 or PMA (Fig. 2).  Although potential
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problems relating to inhibitor specificity cannot be excluded [64,65], we conclude that the
ERK1/2 cascade is primarily responsible for phosphorylation of GSK3 induced by ET-1 or
PMA (possibly via the RSKs), whereas PI3K signalling is required for that induced by
insulin (presumably via PKB/Akt).  Our results for ET-1 contrast with those of Haq et al.
[18] who concluded that phosphorylation of GSK3$(Ser-9) involved activation of PI3K.
MonoS FPLC raises the possibility of separate pools of GSK3.  Apart from the
catalytically-active pool of GSK3 which eluted at 0.11 - 0.22 M NaCl, we detected a pool of
phospho-GSK3"(Tyr-279)/phospho-GSK3$(Tyr-216) in the isocratic wash which was
catalytically inactive (Fig. 4A, C and D).  Although largely unphosphorylated on
GSK3"(Ser-21)/GSK3$(Ser-9) under control conditions, this pool became phosphorylated
following exposure of the cells to insulin and, to a lesser extent, ET-1 (Fig. 4C and E)
indicating that it is not inactive as a consequence of complete phosphorylation of the
inhibitory Ser- residues.  One explanation could be that this pool of GSK3 is inhibited by
complexation with other proteins.
Catalytically-active GSK3 eluted from MonoS columns at 0.11 - 0.22 M NaCl, and
insulin or ET-1 increased phosphorylation GSK3"(Ser-21)/GSK3$(Ser-9), partially
inhibiting this GSK3 (Fig. 4A, E and F).  Other studies used immunoprecipitation to purify
GSK3 [41] for in vitro assays and similarly showed only partial inhibition of GSK3 in
response to insulin or ET-1 [18].  However, such assays are known to be problematical in
certain instances (K. Sakamoto, personal communication) and, although we could detect
substantial GSK3$ activity (only the anti-GSK3$ antibody was suiyable for
immunoprecipitation) in unstimulated cells using immunokinase assays, we were consistently
unable to detect any inhibition by insulin or ET-1.  This (and the partial rather than more
extensive inhibition expected from our FPLC experiments) may relate to the mechanism by
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which phosphorylation of GSK3"(Ser-21)/GSK3$(Ser-9) is inhibitory.  These
phosphorylations compete internally for the binding site of the priming phosphorylation on
GSK3 substrates [71].  In an assay, therefore, an efficient phospho-peptide substrate such as
that used here competes effectively for the same binding site.  We suspect that the
enzyme:substrate ratio is crucial in these assays.
 The mechanisms involved in the anti-hypertrophic effects of (catalytically-active)
GSK3 are not clear [20,21] but presumably involve regulation of gene and protein
expression.  Changes in gene expression may result from degradation of the transcriptional
co-regulator, $-catenin [59,66,67] (as occurs in the Wnt/Frizzled pathway [8-10]), nuclear
exclusion of pro-hypertrophic transcription factors such as the NFATs [18,19] and GATA4
[68], and inhibition of the biological activity of the transcriptional co-regulator, myocardin
[69].  At the level of translation, GSK3 may phosphorylate and reduce the biological activity
of eukaryotic initiation factor 2B [70].  Immunostaining with antibodies to phospho-
GSK3"(Tyr-279)/phospho-GSK3$(Tyr-216) (the only antibody we found to be satisfactory)
showed GSK3 staining predominantly in the nuclei, with much weaker staining in the
cytoplasm (the site of glycogen metabolism) (Fig. 5A).  Thus, GSK3 could to influence gene
expression through phosphorylation of nuclear transcription factors.  A nuclear pool of GSK3
has been detected in other cells [54], and nuclear GSK3 is reportedly increased by
isoprenaline in adult cardiac myocytes [48].  However, we could not see any effect of insulin
or ET-1 on the subcellular localisation of GSK3 in neonatal cells (data not shown).
Given the presence of GSK3 in cardiac myocyte nuclei (Fig. 5A), and that activation
of PKB/Akt with consequent inhibition of GSK3 may represent a signalling pathway that
promotes the changes in gene expression associated with cardiac myocyte hypertrophy
[20,21], we examined the potential changes in AP1 transcription factor activity induced by
26
inhibition of GSK3.  GSK3 phosphorylates Jun family transcription factors at residues
immediately N-terminal to their DNA binding domains and these phosphorylations
negatively regulate their transactivating potentials [52].  For c-Jun, the decrease in
transactivating ability may result from either decreasing DNA binding [72] or by promoting
its degradation [73].  EMSAs with cardiac myocyte nuclear extracts showed that ET-1
increased binding of AP1 components to a DNA consensus sequence (Fig. 6A and B).  This
resulted from an increase in several AP1 components (Fig. 6).  Although insulin or the GSK3
inhibitor 1-azakenpaullone also increased AP1 binding, this was less than that induced by
ET-1 and derived principally from an increase in JunB binding.  The differences between 1-
azakenpaullone and ET-1 on gene expression were further highlighted in our microarray
experiments.  It is clear from Table 1 that, although 1-azakenpaullone does cause changes in
transcript abundances (three of which were confirmed by qPCR, see Fig. 7), these differ from
those induced by ET-1.  Thus, from the perspective of gene expression, cardiac myocyte
hypertrophy induced by ET-1 is unlikely to be mediated by GSK3 to any significant extent.
Key aspects of the hypertrophic response are increases in cell size and myofibrillar
content.  Exposure of cardiac myocytes to 1-azakenpaullone for 24 h resulted in increases in
cell area that resulted primarily from elongation rather than any increase in cell width (Fig.
5C - G).  In contrast, cells exposed to established hypertrophic agonists such as
phenylephrine (Fig. 5C - G) or ET-1 [62] displayed more uniform increases in both length
and width.  Li+ ions have been used extensively as inhibitors of GSK3 (see, for example,
[18]) and may be reasonably effective under physiological ATP/Mg2+ concentrations [64]. 
Myocytes exposed to Li+ also showed evidence of increased cell area and elongation (Fig. 5C
and D) but the effect was less than with 1-azakenpaullone (possibly reflecting the relative
potencies of the inhibitors).  Confusingly, cardiospecific overexpression of GSK3$ in vivo
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also causes an increase in length:width ratio [53].  Myocyte elongation has been previously
observed with the gp130-coupled cytokine receptor agonist, cardiotrophin-1 [74].  As pointed
out by Wollert et al. [74], because of the circumferential nature of myocyte orientation in the
ventricular wall, such lengthening would be expected to be associated in vivo with a 'volume-
overload' hypertrophy (increased ventricular diameter with a proportional increase in
ventricular wall thickness) or a dilated cardiomyopathy (ventricular dilatation with
ventricular wall thinning).  The pattern of hypertrophy induced by phenylephrine as predicted
from Fig. 5C would be a 'pressure-overload' hypertrophy (ventricular wall thickening in the
absence of changes in ventricular diameter).  Although the kenpaullone derivatives are
relatively specific for GSK3, other protein kinases that are potentially pro-hypertrophic (e.g.
Rho kinases [75-77] and PDK1 [78,79]) are also inhibited [36,80].  However, it is the
activation of these kinases that is considered to be pro-hypertrophic.
In conclusion, although ET-1 and insulin do both promote phosphorylation of GSK3
in cardiac myocytes (as previously reported [18]), the signalling pathways involved differ,
with ET-1 operating primarily the ERK1/2 cascade and insulin signalling through PI3K. 
Inhibition of GSK3 by 1-azakenpaullone does produce changes in cardiac myocyte
morphology, but these changes differ from those produced by ET-1 or phenylephrine.  1-
Azakenpaullone induces changes in gene expression but this are dissimilar from those
induced by ET-1, which (in any case) promotes a much more extensive spectrum of changes
(A. Clerk et al., manuscript submitted).  Furthermore, although previous work in cardiac
myocytes has focussed largely on GSK3$, GSK3" is functional in these cells and should not
be ignored.  In the broader context, PKB/Akt is generally viewed as a 'pro-hypertrophic'
kinase in the heart [78,79].  However, PKB/Akt is strongly activated by insulin in cardiac
myocytes [63], and GSK3"(Ser-21) and GSK3$(Ser-9) become rapidly phosphorylated (Fig.
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1C-E), but insulin does not cause myocyte enlargement [62].  Viewed as a whole, these
divergent results are difficult to rationalise in terms of the hypothesis that inhibition of GSK3
represents a primary stimulus to cardiac myocyte hypertrophy [20] or that ET-1-induced
hypertrophy is mediated by inhibition of GSK3 [18].
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Figure Legends
Fig. 1.  Time courses of phosphorylation of GSK3"(Ser-21) and GSK3$(Ser-9) in cardiac
myocytes.  Myocytes were exposed to 100 nM ET-1, 1 :M PMA, or 300 nM insulin for the
times indicated (A-E), or to ET-1, PMA or insulin for 20 min (F and G).  Phosphorylation of
GSK3"(Ser-21) or GSK3$(Ser-9) was estimated by immunoblotting (20 :g protein per lane)
(A - C and F, upper panels).  To detect total GSK3" and GSK3$ (used as loading controls),
antibodies were mixed (A - C and F, lower panels).  D, E and G, Phosphorylation of
GSK3"(Ser-21) or GSK3$(Ser-9) was quantified by calibrated scanning densitometry for 3
(F) or 4 (D and E) separate preparations of myocytes.  Results are means ± S.E.M.  * p<0.01
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relative to control; # p<0.05 relative to insulin (one-way ANOVA with Tukey post-test, n=3
independent myocyte preparations).
Fig. 2.  Effects of inhibition of PI3K or the ERK1/2 cascade on the phosphorylation of
GSK3"(Ser-21) or GSK3$(Ser-9) by 100 nM ET-1, 1 :M PMA, or 300 nM insulin in
cardiac myocytes.  Myocytes were pre-exposed to 50 :M LY294002 or to 10 :M U0126 for
10 min before agonists were added for a further 10 min.  Phosphorylation of GSK3"(Ser-21)
or GSK3$(Ser-9) was estimated by immunoblotting (20 :g protein per lane) (A - C, upper
panels).  To detect total GSK3" and GSK3$ (used as loading controls), antibodies were
mixed (A - C, lower panels).  Phosphorylation of GSK3"(Ser-21) (D) or GSK3$(Ser-9) (E)
was quantified by calibrated scanning densitometry.  Results are means ± S.E.M.  * p<0.05
relative to control; # p<0.05 relative to agonist alone [repeated measures one-way ANOVA
with Tukey post-test; n=4 (ET-1 or insulin) or n=5 (PMA) independent myocyte
preparations].
Fig. 3.  Time courses of phosphorylation of GSK3"(Tyr-279) and GSK3$(Tyr-216) in
cardiac myocytes.  Myocytes were exposed to 100 nM ET-1 (A), 1 :M PMA (B), 300 nM
insulin (C) or 10 :M 1-azakenpaullone (D and E) for the times indicated.  Phosphorylation of
GSK3"(Tyr-279) and GSK3$(Tyr-216) was estimated by immunoblotting (20 :g protein per
lane) (A - D, upper panels).  To detect total GSK3" and GSK3$ (used as loading controls),
antibodies were mixed (A - D, lower panels).  The experiments were repeated 3 times with
similar results.  (E) Phosphorylation of GSK3"(Tyr-279) and GSK3$(Tyr-216) following
exposure of cardiac myocytes to 1-azakenpaullone was quantified by calibrated scanning
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densitometry.  Results are means ± S.E.M.  * p<0.01, # p<0.05 relative to control (one-way
ANOVA with Dunnett post-test for n=3 independent myocyte preparations).
Fig. 4.  MonoS FPLC separation of GSK3..  Myocytes (4 dishes per column) were
unstimulated (Control), or exposed to 100 nM ET-1 or 300 nM insulin for 10 min. (A)
Elution of GSK3 activity from MonoS columns.  The linear NaCl gradient is shown as a
dashed line.  (B) Elution profiles of GSK3 activity (from panel A) were integrated.  Activities
are expressed relative to control values and are means ± S.E.M.  * p<0.01 relative to control,
# p<0.05 relative to insulin (one-way ANOVA with Dunnett post-test for n=3 independent
myocyte preparations).  (C-E) Fractions (20 :l) from control myocytes, or from myocytes
exposed to ET-1 or insulin were immunoblotted for phospho-GSK3"(Tyr-279)/phospho-
GSK3$(Tyr-216) (C), GSK3$ (D), or phospho-GSK3"(Ser-21)/phospho-GSK3$(Ser-9) (E). 
All fractions were surveyed initially, but only fractions containing GSK3 are shown.  The
experiment was repeated 3 times with identical results.  (F) Direct comparison of phospho-
GSK3"(Ser-21)/phospho-GSK3$(Ser-9) (upper panels) or GSK3$ (lower panels) in
fractions from control cells, or from cells exposed to ET-1 or insulin.  The experiment was
repeated 3 times with identical results.
Fig. 5.  Subcellular localisation of GSK3 in cardiac myocytes and effects of GSK3 inhibition
on cardiac myocyte morphology.  GSK3 was detected by immunostaining with anti-phospho-
GSK3"(Tyr-279)/phospho-GSK3$(Tyr-216) (A), and nuclei were counterstained with
Hoechst 33258 (B).  (C) Control myocytes (top left), or myocytes exposed to 100 :M
phenylephrine (top right), 10 mM LiCl (bottom right), or 10 :M 1-azakenpaullone (bottom
left) for 24 h were stained for cardiac troponin T.  Images are representative areas from 4
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independent experiments from separate myocyte preparations.  Areas (D), maximum lengths
(E), maximum widths (F), and maximum length:maximum width ratios (G) of control cells,
and cells exposed to phenylephrine, 1-azakenpaullone or (for cell areas) LiCl were measured
for at least 100 myocytes in each experiment.  Results are means ± S.E.M. for n=4 (D, areas)
or n=3 (E - G, maximum lengths/widths/ratios) independent myocyte preparations for which
each value was taken as the mean of all the cells measured in a particular experiment.  *
p<0.05 or ** p<0.01 relative to controls, # p<0.01 relative to 1-azakenpaullone (repeated
measures one-way ANOVA with Tukey post-test, n=4 (D) or n=3 (E and G) independent
myocyte preparations).
Fig. 6.  Electrophoretic mobility shift assays.  (A) Binding of nuclear extract proteins from
cardiac myocytes exposed to 10 :M 1-azakenpaullone, 300 nM insulin, or 100 nM ET-1 for
30 or 60 min to an AP1 oligonucleotide probe.  (B) AP1 binding (panel A) was quantified by
calibrated scanning densitometry.  Results are means ± S.E.M.  * p<0.05 relative to control
(one-way ANOVA with Dunnett post-test) for n=3 separate preparations of myocytes.  (C)
Supershift EMSA with the indicated antibodies was used to identify proteins bound to the
AP1 probe.  Myocyes were exposed to 1-azakenpaullone, ET-1 or insulin for 60 min. (D and
E) Effects of 10 :M 1-azakenpaullone (D) or 300 nM insulin (E) on JunB abundance as
assessed by immunoblotting of nuclear extracts (20 :g protein per lane) (upper panels). 
Bands were quantified by calibrated scanning densitometry (lower panels).  Results are
means ± S.E.M. for n=3 separate preparations of myocytes.
Fig. 7.  qPCR analysis of the effects of 1-azakenpaullone on mRNA expression of
prostaglandin-endoperoxide synthase 2 (Ptgs2) (A), cyclin G2 (B), or adrenomedullin (C). 
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Cardiac myocytes were exposed to 10 :M 1-azakenpaullone for the times indicated.  Total
RNA was extracted and mRNA expression measured by qPCR.  Results (normalised to
Gapd) are means ± S.E.M. for n=3 (cyclin G2) or n=4 (Ptgs2 or adrenomedullin) independent
myocyte preparations.
Table 1.  Effects of 1-azakenpaullone on gene expression in cardiac myocytes.  Cardiac myocytes were 
unstimulated, or exposed to 10 µM 1-azakenpaullone (1-AKP) or 100 nM ET-1 for 1 h.  RNA was 
extracted and gene expression profiling performed with Affymetrix rat genome 230 2.0 arrays with 
downstream analysis using GeneSpring GX 7.3.1.  Genes with a (p) post-script in section (d) are 
predicted.  Genes were identified with significant differences in expression induced by 1-
azakenpaullone relative to unstimulated controls (FDR<0.05; 2-fold minimum difference).  Results are 
means ± S.E.M. for the expression relative to unstimulated controls (n=3 independent sets of samples, 
each prepared from at least 3 separate myocyte preparations). 
 
Gene Gene Title (probe) Probe 1-AKP ET-1 
 
(a) 1-Azakenpaullone ~ endothelin 
Ddit4 DNA-damage-inducible transcript 4 1368025_at 0.35 ± 0.06 0.16 ± 0.01 
Ppp1r3b Protein phosphatase 1, regulatory subunit 3B 1384262_at 0.46 ± 0.04 0.33 ± 0.04 
  
(b) Endothelin > 1-Azakenpaullone 
Fos 
FBJ murine osteosarcoma viral oncogene 
homolog 1375043_at 2.00 ± 0.15 12.93 ± 1.61 
Nr4a1 Nuclear receptor subfamily 4, group A, member 1 1386935_at 2.30 ± 0.46 19.11 ± 0.91 
Lif Leukemia inhibitory factor  1393728_at 2.57 ± 0.56 10.93 ± 1.21 
Ptgs2 Prostaglandin-endoperoxide synthase 2 1368527_at 3.37 ± 0.95 14.85 ± 1.84 
FosB FBJ osteosarcoma oncogene B 1373759_at 4.68 ± 1.50 117.1 ± 23.1 
 
(c) 1-Azakenpaullone opposite to endothelin 
Errfi1 ERBB receptor feedback inhibitor 1 1373093_at 0.32 ± 0.02 5.41 ± 0.48 
Dusp1 Dual specificity phosphatase 1 1368146_at 0.38 ± 0.04 2.33 ± 0.10 
Klf6 Kruppel-like factor 6 1387060_at 0.39 ± 0.05 4.41 ± 0.56 
Gadd45b Growth arrest and DNA-damage-inducible 45 beta 1372016_at 0.44 ± 0.05 1.69 ± 0.13 
Cited2 
Cbp/p300-interacting transactivator, with Glu/Asp-
rich carboxy-terminal domain, 2 1367602_at 0.46 ± 0.03 4.69 ± 0.17 
  
(d) Endothelin not significantly changed 
Adm Adrenomedullin 1387219_at 0.27 ± 0.01 0.88 ± 0.09 
Ccng2 (p) Cyclin G2  1371953_at 0.32 ± 0.05 0.60 ± 0.05 
Pnrc1 Proline rich 2 1370381_at 0.39 ± 0.07 1.01 ± 0.07 
Pfkfb3 6-Phosphofructo-2-kinase 1390391_at 0.40 ± 0.06 0.70 ± 0.10 
Ptger4 Prostaglandin E receptor 4  1393638_at 0.43 ± 0.05 1.32 ± 0.24 
Rgs4 Regulator of G-protein signaling 4 1368505_at 0.43 ± 0.06 0.81 ± 0.09 
Giot1 
Gonadotropin inducible ovarian transcription 
factor 1 1368775_at 0.45 ± 0.08 0.66 ± 0.19 
Sox18 SRY-box containing gene 18 1381971_at 0.48 ± 0.01 0.92 ± 0.07 
Exo1 (p) Exonuclease 1 1385733_at 0.48 ± 0.05 0.86 ± 0.13 
Rkhd3 (p) Ring finger and KH domain containing 3  1380682_at 0.48 ± 0.03 1.02 ± 0.12 
Spry1 (p) Sprouty homolog 1 (Drosophila) 1379380_at 0.49 ± 0.05 1.00 ± 0.08 
Fzd8 Frizzled homolog 8 (Drosophila) 1383721_at 0.49 ± 0.05 1.00 ± 0.04 
Tnf Tumor necrosis factor  1391384_at 0.50 ± 0.08 0.92 ± 0.10 
Isl2 Insulin related protein 2 1369530_at 2.04 ± 0.27 1.64 ± 0.40 
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